Automate Your Wheel Strategy on ILMN
With Tiblio's Option Bot, you can configure your own wheel strategy including ILMN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ILMN
- Rev/Share 27.4808
- Book/Share 15.2628
- PB 8.8306
- Debt/Equity 1.0819
- CurrentRatio 1.4251
- ROIC 0.1203
- MktCap 20594384000.0
- FreeCF/Share 6.4103
- PFCF 20.5944
- PE 29.9085
- Debt/Assets 0.417
- DivYield 0
- ROE 0.2998
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ILMN | Daiwa Securities | Outperform | Neutral | -- | $94 | Aug. 12, 2025 |
| Downgrade | ILMN | Scotiabank | Sector Outperform | Sector Perform | -- | $125 | July 11, 2025 |
| Reiterated | ILMN | Citigroup | -- | Neutral | $130 | $90 | March 4, 2025 |
| Downgrade | ILMN | HSBC Securities | Buy | Hold | -- | $100 | Feb. 28, 2025 |
| Downgrade | ILMN | Barclays | Equal Weight | Underweight | $130 | $100 | Feb. 10, 2025 |
| Downgrade | ILMN | TD Cowen | Buy | Hold | $177 | $140 | Feb. 7, 2025 |
| Downgrade | ILMN | Citigroup | Buy | Neutral | $190 | $165 | Dec. 11, 2024 |
| Upgrade | ILMN | HSBC Securities | Hold | Buy | -- | $180 | Oct. 17, 2024 |
| Upgrade | ILMN | Argus | Hold | Buy | -- | -- | Aug. 28, 2024 |
| Upgrade | ILMN | Daiwa Securities | Neutral | Buy | $120 | $154 | Aug. 16, 2024 |
News
Illumina (ILMN) Surges 3.3%: Is This an Indication of Further Gains?
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Illumina (ILMN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
Can These 5 Relative Price Strength Stocks Lead in 2026?
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
U.S. stocks are heading toward the end of the year with clear momentum, as the major indexes continue to hover near record levels. While short-term pauses have appeared, they have been shallow, suggesting that investors are positioning for a constructive finish to the year and a positive handoff into the new one.
Read More
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
Published: December 11, 2025 by: PRNewsWire
Sentiment: Neutral
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO and MENLO PARK, Calif.
Read More
Bet on These 3 Stocks With Upgraded Broker Ratings Amid Uncertainties
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Illumina, Commercial Metals and Newmont have all seen broker upgrades, signaling bullish momentum amid market uncertainties.
Read More
Illumina (ILMN) Moves to Strong Buy: Rationale Behind the Upgrade
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Illumina, Inc. (ILMN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Published: November 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Illumina, Inc. ( ILMN ) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 9:20 AM EST Company Participants Jacob Thaysen - CEO & Director Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC Okay. Good morning, everybody.
Read More
Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study
Published: November 12, 2025 by: PRNewsWire
Sentiment: Neutral
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood pressure and cholesterol Results demonstrate the advantages of WGS over WES and genotyping arrays for assessing genetic risk and identifying drug target candidates. SAN DIEGO , Nov. 12, 2025 /PRNewswire/ -- A study published today in Nature , authored by Illumina, Inc. (NASDAQ: ILMN) scientists and by collaborators from The University of Queensland demonstrates the importance of whole-genome sequencing (WGS) to more fully capture the genetics underlying complex human traits …
Read More
ALKS or ILMN: Which Is the Better Value Stock Right Now?
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Alkermes (ALKS) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks
Published: November 10, 2025 by: PRNewsWire
Sentiment: Neutral
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed Sydney Mass Spectrometry is the first facility in the wider Asia Pacific region to offer Illumina Protein Prep, adding to a growing list of institutions revealing biological insights with exceptional clarity at scale Recent collaborations and projects including Genomics England and PRECISE-SG100K highlight advancements in proteomic profiling across diverse populations and research areas SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Protein Prep is delivering the …
Read More
DNA Sequencing Firm Illumina Sees Strong Clinical Market Momentum, Stock Soars
Published: October 31, 2025 by: Benzinga
Sentiment: Positive
Illumina Inc. (NASDAQ:ILMN) stock is trading higher after the company reported better-than-expected third-quarter earnings.
Read More
KMDA or ILMN: Which Is the Better Value Stock Right Now?
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada (KMDA) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Read More
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
Published: October 15, 2025 by: PRNewsWire
Sentiment: Neutral
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map variants SAN DIEGO , Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped read technology, evaluating its performance on regions of the genome that traditional short-read technologies historically have not resolved. GeneDx's early results illustrate the ability of constellation to rapidly identify hard-to-detect variants implicated in rare disease.
Read More
Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights
Published: October 15, 2025 by: PRNewsWire
Sentiment: Neutral
At ASHG, an early access customer from the London Health Sciences Center Research Institute will demonstrate the power of the 5-base genome for accelerating resolution of rare disease cases Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic inquiry, providing researchers with new tool for precision medicine breakthroughs SAN DIEGO , Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the release of its novel 5-base solution, enabling researchers to pursue broader biological questions with accuracy and ease. The 5-base solution marks a major advancement in scalable multiomic analysis, enabling simultaneous detection of both genomic variants and DNA …
Read More
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
ILMN Stock Set to Benefit From the Launch of New BioInsight Division
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.
Read More
Illumina launches new business to accelerate technology and data-driven discovery
Published: October 01, 2025 by: PRNewsWire
Sentiment: Neutral
New business focuses on developing data assets, software, and AI to fuel life science breakthroughs Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO , Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of researchers and pharma companies to access and interpret ever larger-scale multiomic data. By bringing together Illumina's strengths across sequencing, data analysis, software and AI, BioInsight will empower customers and partners with solutions to identify …
Read More
KMDA vs. ILMN: Which Stock Is the Better Value Option?
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada (KMDA) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors are showing growing interest in the rapidly expanding Precision Oncology market, which is expected to witness a compound annual growth rate (CAGR) of 8% between 2025 and 2030, according to Grand View Research. Tempus AI TEM and Illumina ILMN are two key players with significant presence in this market.
Read More
ILMN Stock vs. IQV Stock
Published: September 26, 2025 by: Forbes
Sentiment: Negative
Amid increased competition from China's MGI Tech, Illumina's stock (NASDAQ: ILMN) has dropped by 11% in a week. MGI Tech's DNA sequencers are reportedly gaining market share, and despite a recent decline in its international sales due to U.S. sanctions, MGI Tech's global market presence remains strong.
Read More
Here's Why Illumina (ILMN) is a Strong Momentum Stock
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Illumina advances personalized cancer care with new pharma development partnerships
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker SAN DIEGO , Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight™ Oncology (TSO) Comprehensive genomic profiling test.
Read More
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
Published: September 18, 2025 by: PRNewsWire
Sentiment: Neutral
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO , Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD).
Read More
ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The Illumina Protein Prep rollout boosts multiomics, strengthens disease insights and supports ILMN stock momentum.
Read More
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
Published: September 03, 2025 by: PRNewsWire
Sentiment: Neutral
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, customers commend scale, high consistency, and easy sample to insights workflow Launch follows Illumina's announcement of agreement to acquire SomaLogic SAN DIEGO , Sept. 3, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of Illumina Protein Prep, an assay introducing superior performance for next-generation sequencing (NGS) based proteomics discovery at scale.
Read More
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
KMDA vs. ILMN: Which Stock Is the Better Value Option?
Published: August 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Illumina (ILMN) Reliance on International Sales: What Investors Need to Know
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
About Illumina, Inc. (ILMN)
- IPO Date 2000-07-28
- Website https://www.illumina.com
- Industry Medical - Diagnostics & Research
- CEO Jacob Thaysen
- Employees 8970